Across TCGA pan-cancer cohorts, IGHV1-18 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV1-18 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IGHV1-18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV1-18 expression acts as an unfavorable survival marker.

OV, LGG, and LUAD are the cancer types where IGHV1-18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.204	0.541	.017	12	view →
LGG	DFS	Median	All	0.156	0.753	<.001	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGHV1-18 tumor-vs-normal RNA expression · all IGHV1-18 data types